Adjuvant Pembrolizumab Approved in EU for Stage III Melanoma

December 17, 2018 – The European Commission has approved pembrolizumab as an adjuvant treatment for patients with resected, stage III melanoma with lymph node involvement, according to Merck (MSD), the manufacturer of the PD-1 inhibitor. The approval was based on findings from the phase III EORTC 1325-MG/KEYNOTE-054 trial. For its review, the European Medicines Agency requested an updated recurrence-free survival (RFS) analysis with 7 months’ of … (leggi tutto)